Freestone Capital Holdings LLC Raises Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Freestone Capital Holdings LLC has increased its stake in Thermo Fisher Scientific by 4.5%, owning a total of 27,364 shares valued at approximately $13.6 million.
• Various analysts have updated their price targets for Thermo Fisher Scientific, with Wells Fargo lowering it to $565, while UBS, Barclays, and Robert W. Baird have raised theirs to between $490 and $567.
• Thermo Fisher Scientific has declared a quarterly dividend of $0.43 per share, with a payment date set for October 15th, representing an annual yield of approximately 0.4%.

Freestone Capital Holdings LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,364 shares of the medical research company's stock after purchasing an additional 1,167 shares during the quarter. Freestone Capital Holdings LLC's holdings in Thermo Fisher Scientific were worth $13,616,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TMO. Corient IA LLC bought a new position in Thermo Fisher Scientific during the first quarter worth $249,000. George Kaiser Family Foundation acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at $255,000. Northwest & Ethical Investments L.P. boosted its stake in shares of Thermo Fisher Scientific by 44.5% in the 1st quarter. Northwest & Ethical Investments L.P. now owns 27,758 shares of the medical research company's stock valued at $13,812,000 after purchasing an additional 8,542 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Thermo Fisher Scientific by 1.3% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 33,163 shares of the medical research company's stock valued at $16,502,000 after purchasing an additional 414 shares in the last quarter. Finally, Forvis Mazars Wealth Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 6.3% in the 1st quarter. Forvis Mazars Wealth Advisors LLC now owns 7,624 shares of the medical research company's stock valued at $3,794,000 after purchasing an additional 452 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at $52,037,916.68. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,400 shares of company stock valued at $8,345,792 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. UBS Group boosted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Royal Bank Of Canada decreased their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. William Blair initiated coverage on Thermo Fisher Scientific in a report on Monday. They set an "outperform" rating for the company. Finally, Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Trading Down 2.3%

TMO traded down $11.3820 during trading on Thursday, hitting $483.4280. 1,360,016 shares of the stock were exchanged, compared to its average volume of 2,488,745. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The firm has a 50 day simple moving average of $439.69 and a 200 day simple moving average of $458.78. The firm has a market cap of $182.55 billion, a price-to-earnings ratio of 27.96, a P/E/G ratio of 2.66 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.